Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 18, 2022 - Issue 1
Submit an article Journal homepage
1,330
Views
0
CrossRef citations to date
0
Altmetric
Pneumococcal – Letters

Response to article by Johnna Perdrizet et al.,“Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants”

Jorge A. Gómeza Vaccine Department, GlaxoSmithKline, Buenos Aires, ArgentinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5459-4973View further author information
ORCID Icon,
Thatiana de Jesus Pereira Pintob Vaccine Department, GlaxoSmithKline, Rio de Janeiro, BrazilView further author information
,
Javier Nieto Guevarac Vaccine Department, GlaxoSmithKline, Panama City, PanamaView further author information
&
Tatiana Guimarães de Noronhad Institute of Technology for Immunobiologicals of Bio-Manguinhos, FIOCRUZ, Rio de Janeiro, BrazilView further author information
Article: 1894898 | Published online: 19 May 2021

References

  • Perdrizet J, Santana CFS, Senna T, Alexandre RF, Sini De Almeida R, Spinardi J, Wasserman M. Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants. Hum Vaccin Immunother. 2020 Sep 23;1–3. PMID: 32966176. doi:10.1080/21645515.2020.1809266.
  • Ministry of Health. Informatics department of the Brazilian unified health system. DATASUS web page. 2020. [accessed 2020 Dec 20]. https://datasus.saude.gov.br/informacoes-de-saude-tabnet/.
  • Carrasquilla G, Porras-Ramírez A, Martinez S, DeAntonio R, Devadiga R, Talarico C, Caceres DC, Castrejon MM, Juliao P. Trends in all-cause pneumonia and otitis media in children aged <2 years following pneumococcal conjugate vaccine introduction in Colombia. Hum Vaccin Immunother. Forthcoming. doi:10.1080/21645515.2020.1805990.
  • Sartori AL, Minamisava R, Bierrenbach AL, Toscano CM, Afonso ET, Morais-Neto OL, Antunes JLF, Cristo EB, Andrade AL. Reduction in all-cause otitis media-related outpatient visits in children after PCV10 introduction in Brazil. PLoS ONE. 2017;12(6):e0179222. doi:10.1371/journal.pone.0179222.
  • Mott MP, Caierão J, Cunha GR, Del Maschi MM, Pizzutti K, d’Azevedo P, Dias CAG. Emergence of serotype 19A streptococcus pneumoniae after PCV10 associated with a ST320 in adult population, in Porto Alegre, Brazil. Epidemiol Infect. 2019;147:e93. PMID: 30869012; PMCID: PMC6518833. doi:10.1017/S0950268819000013.
  • Snedecor SJ, Strutton DR, Ciuryla V, Schwartz EJ, Botteman MF. Transmission-dynamic model to capture the indirect effects of infant vaccination with Prevnar (7-valent pneumococcal conjugate vaccine (PCV7)) in older populations. Vaccine. 2009;27(34):4694–703. doi:10.1016/j.vaccine.2009.05.062.
  • Caro JJ, Briggs AH, Siebert U, Kuntz KM; ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling good research practices – overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Med Decis Making. 2012;32(5):667–77. doi:10.1177/0272989X12454577.
  • Deceuninck G, De Serres G, Boulianne N, Lefebvre B, De Wals P. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. Vaccine. 2015;33(23):2684–89. doi:10.1016/j.vaccine.2015.04.005.
  • Domingues CM, Verani JR, Montenegro Renoiner EI, De Cunto Brandileone MC, Flannery B, De Oliveira LH, Santos JB, De Moraes JC; Brazilian Pneumococcal Conjugate Vaccine Effectiveness Study Group. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med. 2014;2(6):464–71. doi:10.1016/S2213-2600(14)70060-8.
  • Jokinen J, Rinta-Kokko H, Siira L, Palmu AA, Virtanen MJ, Nohynek H, Virolainen-Julkunen A, Toropainen M, Nuorti JP. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children–a population-based study. PLoS One. 2015;10(3):e0120290. doi:10.1371/journal.pone.0120290.
  • De Oliveira LH, Camacho LA, Coutinho ES, Martinez-Silveira MS, Carvalho AF, Ruiz-Matus C, Toscano CM. Impact and effectiveness of 10 and 13-valent pneumococcal conjugate vaccines on hospitalization and mortality in children aged less than 5 years in Latin American countries: a systematic review. PLoS One. 2016;11(12):e0166736. doi:10.1371/journal.pone.0166736.
  • Cohen O, Knoll M, O’Brien K, Ramakrishnan M, Constenla D, Privor-Dumm L, Buss-Younkin J, Farrar J, Pilishvili T, Whitney C, et al., Pneumococcal conjugate vaccine (PCV) product assessment I.V.A.C. IVAC, Editor. 2017. [accessed 2020 Dec 20]. https://www.jhsph.edu/ivac/wp-content/uploads/2018/05/pcv-product-assessment-april-25-2017.pdf
  • WHO Regional Technical Advisory groups on immunization in [accessed 2020 Dec 20]. http://www.who.int/immunization/sage/regional/en/.
  • Gomez JA, Lopes De Abreu AJ, Caceres DC, Nieto J, Ortega-Barria E. Estimated annual health and cost impact of PHiD-CV immunization program in Brazil. Pediatr Infect Dis J. 2019;38:e260–e265. doi:10.1097/INF.0000000000002436.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.